Besides, LAGE-1 has a tumor-specific expression similar to that of MAGE-A1 and NY-ESO-1, so it is possible to become a target antigen for anti-tumor immunotherapy of esophageal carcinoma (Lethe et al. 1998). Here, CTAG2 is linked to neoplasm.